RCEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AVITA Medical's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.78.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AVITA Medical couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.
The historical rank and industry rank for AVITA Medical's Cash-to-Debt or its related term are showing as below:
During the past 13 years, AVITA Medical's highest Cash to Debt Ratio was No Debt. The lowest was 0.78. And the median was 118.07.
The historical data trend for AVITA Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AVITA Medical Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Dec22 | Dec23 | Dec24 | |||||||||||
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
38.41 | 126.13 | 86.43 | 2.10 | 0.78 |
AVITA Medical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.10 | 1.52 | 1.20 | 0.97 | 0.78 |
For the Medical Devices subindustry, AVITA Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
AVITA Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 35.885 | / | (0.9 | + | 45.085) | |
= | 0.78 |
AVITA Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 35.885 | / | (0.9 | + | 45.085) | |
= | 0.78 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (NAS:RCEL) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of AVITA Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Mcnamara | director | C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750 |
David D O'toole | officer: CFO | 1640 MARENGO STREET, LOS ANGELES CA 90033 |
Suzanne Crowe | director | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
James Corbett | director | 2 GOODYEAR, IRVINE CA 92618 |
Jeremy Curnock Cook | director | TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101 |
Donna Shiroma | officer: General Counsel | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Cary Guy Vance | director | 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043 |
Michael S Perry | director, officer: Chief Executive Officer | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Jan Stern Reed | director | C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015 |
Michael Holder | officer: Chief Financial Officer | 6170 RESEARCH RD., STE 103, FRISCO TX 75034 |
Kathy M. Mcgee | officer: Chief Operating Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Sean Ekins | officer: Sr. VP of Finance | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
David Mcintyre | officer: Chief Financial Officer | SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000 |
Erin Liberto | officer: Chief Commercial Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Andrew Quick | officer: Chief Technology Officer | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 200, VALENCIA CA 91355 |
From GuruFocus
By GuruFocus News • 10-02-2024
By GuruFocus News • 02-13-2025
By Marketwired • 10-10-2024
By Marketwired • 03-17-2025
By Marketwired • 12-18-2024
By Marketwired • 02-13-2025
By Marketwired • 09-12-2024
By Marketwired • 11-07-2024
By GuruFocus News • 11-19-2024
By GuruFocus News • 02-22-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.